BOUCHÉ , O.

Last name: BOUCHÉ

First name: O.

April 2018 (v1)

Journal article

Metadata-only

OC-0284: First results of the French cohort ANABASE : treatment and outcome in non-metastatic anal cancer

Vendrely, V. Lemanski, C. Francois, E.

International audience

Uploaded on: December 4, 2022
September 8, 2017 (v1)

Conference paper

Metadata-only

Bevacizumab (Bev) or cetuximab (Cet) plus chemotherapy after progression with bevacizumab plus chemotherapy in patients with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Final analysis of a French randomized, multicenter, phase II study (PRODIGE 18)

Bennouna, J. Hiret, S. Borg, C.

International audience

Uploaded on: March 26, 2023
October 1, 2017 (v1)

Journal article

Metadata-only

Late toxicities and clinical outcome at 5 years of the ACCORD 12/0405-PRODIGE 02 trial comparing two neoadjuvant chemoradiotherapy regimens for intermediate-risk rectal cancer

Azria, D. Doyen, J. Jarlier, M.

BackgroundOutcome of intermediate risk rectal cancer may be improved by the addition of oxaliplatin during 5-fluoruracil concomitant neoadjuvant chemoradiotherapy. The purpose of this study is to analyze the main clinical results of the ACCORD12 trial (NCT00227747) in rectal cancer after 5 years of follow-up.Patients and methodsInclusion...

Uploaded on: March 26, 2023
October 7, 2016 (v1)

Conference paper

Metadata-only

Prognostic factor analysis for elderly patients treated for metastatic colorectal cancer in the randomized phase II trial PRODIGE 20

Aparicio, T. Bouché, O. Francois, E.

International audience

Uploaded on: February 28, 2023
January 1, 2018 (v1)

Journal article

Metadata-only

Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial-PRODIGE 20 study results

Aparicio, T. Bouché, O. Taieb, J.

Background :Metastatic colorectal cancer frequently occurs in elderly patients. Bevacizumab in combination with front line chemotherapy (CT) is a standard treatment but some concern raised about tolerance of bevacizumab for these patients. The purpose of PRODIGE 20 was to evaluate tolerance and efficacy of bevacizumab according to specific end...

Uploaded on: March 26, 2023

BOUCHÉ , O.

Recent uploads